| Jyoti B Ganji, MD | |
|
80 B Veterans Blvd, Acoma, NM 87034 | |
| (505) 552-5300 | |
| (505) 552-5490 |
| Full Name | Jyoti B Ganji |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 80 B Veterans Blvd, Acoma, New Mexico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255328266 | NPI | - | NPPES |
| 1979627 | Medicaid | LA | |
| H3451 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 06964R (Louisiana) | Primary |
| 208600000X | Surgery | 22011 (Kansas) | Secondary |
| 208600000X | Surgery | 13972 (Arizona) | Secondary |
| Entity Name | Emergency Staffing Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477590974 PECOS PAC ID: 9830001650 Enrollment ID: O20050610000177 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Entity Name | Rapid Urgent Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285970780 PECOS PAC ID: 0840437174 Enrollment ID: O20130506000203 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Entity Name | Ess Hospitalist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881967305 PECOS PAC ID: 6103085295 Enrollment ID: O20130515000072 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Entity Name | Jena Ess Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235544115 PECOS PAC ID: 7810116258 Enrollment ID: O20140916002675 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Entity Name | Jena Ess Hospitalist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144635020 PECOS PAC ID: 5294954533 Enrollment ID: O20140918000317 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20140930001176 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Entity Name | Concord North Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952761173 PECOS PAC ID: 2860791688 Enrollment ID: O20170922000452 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Entity Name | Leatherwood Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760946313 PECOS PAC ID: 0749521250 Enrollment ID: O20190410002335 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Entity Name | South Central Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427611854 PECOS PAC ID: 6507195492 Enrollment ID: O20191022002061 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jyoti B Ganji, MD Po Box 130, San Fidel, NM 87049-0130 Ph: (505) 552-5300 | Jyoti B Ganji, MD 80 B Veterans Blvd, Acoma, NM 87034 Ph: (505) 552-5300 |
News Archive
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Politico notes that enrollment in online marketplaces in California, Florida and Texas will have an outsized impact on whether the Obama administration achieves its nationwide goals for expanding coverage. Other outlets report how states will market the new insurance plans and how some Americans are confused by health insurance generally and Obamacare in particular.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.
› Verified 6 days ago